Early 2009: Partner IDX899 program. (IDIX had guided for a deal by the end of 2008; please see #msg-28959639 for musings on the terms of such a partnership).
After partnership deal is announced: Start IDX899 phase-2a combination study (IDX899+Truvada vs Sustiva+Truvada) in first- and second-line patients.
HCV
1Q09: Start IDX184 phase-2a combination study (SoC ± IDX184). (The phase-1/2 monotherapy study is a prerequisite: #msg-34493338.)
April 2009: Report preliminary results of IDX184 phase-2a study at EASL.
1H09: File IND for IDX375 non-nucleoside polymerase inhibitor.
1H09: File IND for IDX136 and IDX316 protease inhibitors.
Market Data 
Markets 
AI
